James Ballenger to Female
This is a "connection" page, showing publications James Ballenger has written about Female.
Connection Strength
0.407
-
A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimul. 2008 Apr; 1(2):112-21.
Score: 0.016
-
Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry. 2004 Dec; 65(12):1696-707.
Score: 0.013
-
Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder. Psychol Med. 2003 Apr; 33(3):511-8.
Score: 0.011
-
A brief scale for assessing patients' satisfaction with care in outpatient psychiatric services. Psychiatr Serv. 2001 Jun; 52(6):816-9.
Score: 0.010
-
A controlled trial of daily left prefrontal cortex TMS for treating depression. Biol Psychiatry. 2000 Nov 15; 48(10):962-70.
Score: 0.010
-
Recognizing the patient with social anxiety disorder. Int Clin Psychopharmacol. 2000 Jul; 15 Suppl 1:S1-5.
Score: 0.009
-
Multiple previous alcohol detoxifications are associated with decreased medial temporal and paralimbic function in the postwithdrawal period. Alcohol Clin Exp Res. 1999 Jun; 23(6):1077-84.
Score: 0.009
-
Sleep Deprivation in social phobia and generalized anxiety disorder. Biol Psychiatry. 1998 Jun 01; 43(11):840-2.
Score: 0.008
-
Comorbidity of panic and depression: implications for clinical management. Int Clin Psychopharmacol. 1998 Apr; 13 Suppl 4:S13-7.
Score: 0.008
-
Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998 Jan; 155(1):36-42.
Score: 0.008
-
Sleep deprivation in panic disorder and obsessive-compulsive disorder. Can J Psychiatry. 1997 Nov; 42(9):982-3.
Score: 0.008
-
Clinical evaluation of venlafaxine. J Clin Psychopharmacol. 1996 Jun; 16(3 Suppl 2):29S-35S; discussion 35S-36S.
Score: 0.007
-
The DSM-IV panic disorder field trial: panic attack frequency and functional disability. Anxiety. 1996; 2(4):157-66.
Score: 0.007
-
Body dysmorphic disorder in patients with anxiety disorders and major depression: a comorbidity study. Am J Psychiatry. 1995 Nov; 152(11):1665-7.
Score: 0.007
-
Sertraline in social phobia. J Clin Psychopharmacol. 1995 Oct; 15(5):372-3.
Score: 0.007
-
CSF isatin is elevated in bulimia nervosa. Biol Psychiatry. 1995 Apr 01; 37(7):481-3.
Score: 0.007
-
Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry. 1995 Mar; 56(3):118-21.
Score: 0.006
-
Comorbidity of axis I psychiatric disorders in bulimia nervosa. J Clin Psychiatry. 1995 Feb; 56(2):77-80.
Score: 0.006
-
Plasma pyridoxal phosphate in anxiety disorders. Biol Psychiatry. 1994 Nov 01; 36(9):606-8.
Score: 0.006
-
Plasma and CSF HVA levels in panic patients with comorbid social phobia. Biol Psychiatry. 1994 Sep 15; 36(6):425-7.
Score: 0.006
-
Somatic symptoms in generalized anxiety disorder with and without comorbid psychiatric disorders. Am J Psychiatry. 1994 Jun; 151(6):930-2.
Score: 0.006
-
Panic disorder and gastrointestinal symptoms: findings from the NIMH Epidemiologic Catchment Area project. Am J Psychiatry. 1994 Jan; 151(1):64-70.
Score: 0.006
-
Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry. 1993 Aug; 150(8):1216-8.
Score: 0.006
-
CSF cholecystokinin octapeptide in patients with bulimia nervosa and in normal comparison subjects. Am J Psychiatry. 1993 Jul; 150(7):1099-101.
Score: 0.006
-
Comment on the London/Toronto Study of Alprazolam and Exposure in Panic Disorder with Agoraphobia. Br J Psychiatry. 1993 Jun; 162:788-9; discussion 790-4.
Score: 0.006
-
Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. J Clin Psychiatry. 1993 Jun; 54(6):224-8.
Score: 0.006
-
Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics. 1993 May-Jun; 34(3):229-34.
Score: 0.006
-
Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients. J Psychiatr Res. 1993 Apr-Jun; 27(2):161-72.
Score: 0.006
-
Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull. 1993; 29(2):183-8.
Score: 0.006
-
CSF beta-endorphin and dynorphin in bulimia nervosa. Am J Psychiatry. 1992 Aug; 149(8):1086-90.
Score: 0.005
-
The effects of pregnancy on preexisting panic disorder. J Clin Psychiatry. 1992 Jun; 53(6):201-3.
Score: 0.005
-
The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist, abecarnil (ZK 112-119), in generalized anxiety disorder. Adv Biochem Psychopharmacol. 1992; 47:431-47.
Score: 0.005
-
Cardiovascular status of panic disorder patients with and without prominent cardiac symptoms. Psychosomatics. 1992; 33(1):81-4.
Score: 0.005
-
Cocaine-induced psychosis. J Clin Psychiatry. 1991 Dec; 52(12):509-12.
Score: 0.005
-
Treatment of social phobia with bupropion. J Clin Psychopharmacol. 1991 Aug; 11(4):276-7.
Score: 0.005
-
Effect of alprazolam on depression in panic disorder. J Clin Psychopharmacol. 1991 Apr; 11(2):145-6.
Score: 0.005
-
The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder. Psychopharmacol Bull. 1991; 27(2):171-9.
Score: 0.005
-
Pergolide mesylate treatment of cocaine withdrawal. J Clin Psychiatry. 1991 Jan; 52(1):39-40.
Score: 0.005
-
Brain MRI in obsessive-compulsive disorder. Psychiatry Res. 1991 Jan; 36(1):45-9.
Score: 0.005
-
Panic and phobic disorders in patients with obsessive compulsive disorder. J Clin Psychiatry. 1990 Nov; 51(11):456-8.
Score: 0.005
-
Rapid response of patients simultaneously treated with lithium and nortriptyline. J Clin Psychiatry. 1990 Mar; 51(3):124-5.
Score: 0.005
-
Phenelzine treatment of panic disorder: lack of effect on pyridoxal phosphate levels. J Clin Psychopharmacol. 1989 Dec; 9(6):428-31.
Score: 0.005
-
Refractory rapid cycling unipolar depression responds to lithium and carbamazepine treatment. J Clin Psychiatry. 1989 Sep; 50(9):356-7.
Score: 0.004
-
Three cases of panic disorder with agoraphobia in children. Am J Psychiatry. 1989 Jul; 146(7):922-4.
Score: 0.004
-
Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull. 1989; 25(1):68-70.
Score: 0.004
-
Electroencephalography during sleep of patients with panic disorder. J Neuropsychiatry Clin Neurosci. 1989; 1(4):372-6.
Score: 0.004
-
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry. 1988 May; 45(5):413-22.
Score: 0.004
-
Alcohol detoxification and withdrawal seizures: clinical support for a kindling hypothesis. Biol Psychiatry. 1988 Mar 01; 23(5):507-14.
Score: 0.004
-
Precursor amino acid concentrations in normal weight bulimics and normal controls. Prog Neuropsychopharmacol Biol Psychiatry. 1988; 12(6):893-8.
Score: 0.004
-
Alprazolam in the treatment of social phobia. J Clin Psychiatry. 1988 Jan; 49(1):17-9.
Score: 0.004
-
Sexual side effects of alprazolam. Am J Psychiatry. 1987 Feb; 144(2):254-5.
Score: 0.004
-
Can panic disorder present as irritable bowel syndrome? J Clin Psychiatry. 1986 Sep; 47(9):470-3.
Score: 0.004
-
Conditioning and sensitisation in the longitudinal course of affective illness. Br J Psychiatry. 1986 Aug; 149:191-201.
Score: 0.004
-
Psychopharmacology of the anxiety disorders. Psychiatr Clin North Am. 1984 Dec; 7(4):757-71.
Score: 0.003
-
Tricyclic antidepressant use in a patient with bundle branch blocks and ventricular ectopy. J Clin Psychiatry. 1984 Aug; 45(8):353-5.
Score: 0.003
-
Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacol Bull. 1984; 20(3):572-84.
Score: 0.003
-
Bupropion sustained release for panic disorder. Psychopharmacol Bull. 2003; 37(4):66-72.
Score: 0.003
-
Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry. 1980 Jul; 137(7):782-90.
Score: 0.002
-
Bupropion-SR in treatment of social phobia. Depress Anxiety. 2000; 12(2):111-3.
Score: 0.002
-
The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999 Jul; 60(7):427-35.
Score: 0.002
-
Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder. J Clin Psychiatry. 1999 May; 60(5):299-301.
Score: 0.002
-
Feasibility of using fMRI to study mothers responding to infant cries. Depress Anxiety. 1999; 10(3):99-104.
Score: 0.002
-
Panic disorder and quality of life: variables predictive of functional impairment. Am J Psychiatry. 1997 Jun; 154(6):766-72.
Score: 0.002
-
A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry. 1997; 58 Suppl 11:11-8.
Score: 0.002
-
Comorbidity of posttraumatic stress disorder and irritable bowel syndrome. J Clin Psychiatry. 1996 Dec; 57(12):576-8.
Score: 0.002
-
Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol Psychiatry. 1996 Apr 15; 39(8):703-7.
Score: 0.002
-
Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry. 1995 Oct; 167(4):487-94.
Score: 0.002
-
A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry. 1995 Apr 01; 37(7):462-6.
Score: 0.002
-
Infrequent panic attacks: psychiatric comorbidity, personality characteristics and functional disability. J Psychiatr Res. 1995 Mar-Apr; 29(2):121-31.
Score: 0.002
-
Predictors of response to alprazolam and placebo in patients with panic disorder. J Affect Disord. 1994 Jan; 30(1):5-13.
Score: 0.001
-
Cerebrospinal fluid thyrotropin-releasing hormone concentrations in patients with anxiety disorders. J Neuropsychiatry Clin Neurosci. 1993; 5(3):335-7.
Score: 0.001
-
Eating disorders and social phobia. Arch Gen Psychiatry. 1993 Jan; 50(1):70.
Score: 0.001
-
Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry. 1992 Nov; 149(11):1556-62.
Score: 0.001
-
CSF diazepam-binding inhibitor concentrations in panic disorder. Biol Psychiatry. 1992 Oct 15; 32(8):712-6.
Score: 0.001
-
Discontinuation of alprazolam after long-term treatment of panic-related disorders. J Clin Psychopharmacol. 1992 Oct; 12(5):352-4.
Score: 0.001
-
CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry. 1992 May; 149(5):691-3.
Score: 0.001
-
A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol. 1992 Apr; 12(2):96-103.
Score: 0.001
-
CSF opioids in panic disorder. Biol Psychiatry. 1991 Sep 01; 30(5):512-4.
Score: 0.001
-
Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991 Aug 01; 30(3):225-32.
Score: 0.001
-
CSF monoamine levels in normal-weight bulimia: evidence for abnormal noradrenergic activity. Am J Psychiatry. 1990 Feb; 147(2):225-9.
Score: 0.001
-
Early family experiences of women with bulimia and depression. Arch Psychiatr Nurs. 1990 Feb; 4(1):43-52.
Score: 0.001
-
Sequence of improvement in agoraphobia with panic attacks. J Psychiatr Res. 1990; 24(1):1-8.
Score: 0.001
-
CSF prostaglandin-E in agoraphobia with panic attacks. Biol Psychiatry. 1989 Jul; 26(3):257-64.
Score: 0.001
-
Secondary depression in panic disorder and agoraphobia. II. Dimensions of depressive symptomatology and their response to treatment. J Affect Disord. 1989 Jan-Feb; 16(1):49-58.
Score: 0.001
-
Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia. J Behav Ther Exp Psychiatry. 1988 Jun; 19(2):119-26.
Score: 0.001
-
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. Arch Gen Psychiatry. 1988 May; 45(5):423-8.
Score: 0.001
-
Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry. 1987 May; 144(5):664-5.
Score: 0.001
-
The effects of lithium on neuroendocrine function in affectively ill patients. Acta Psychiatr Scand. 1986 May; 73(5):524-8.
Score: 0.001
-
Dopaminergic effects of carbamazepine. Relationship to clinical response in affective illness. Arch Gen Psychiatry. 1986 Apr; 43(4):392-6.
Score: 0.001
-
Neuroendocrine effects of carbamazepine in patients with affective illness. Epilepsia. 1986 Mar-Apr; 27(2):156-60.
Score: 0.001
-
Neuroendocrine effects of the dopamine agonist piribedil in depressed patients. Clin Neuropharmacol. 1986; 9(5):448-55.
Score: 0.001
-
The dexamethasone suppression test in agoraphobia. J Clin Psychopharmacol. 1985 Apr; 5(2):100-2.
Score: 0.001
-
The neurobiology of some dimensions of personality. Int Rev Neurobiol. 1984; 25:391-436.
Score: 0.001
-
Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry. 1983 Dec; 140(12):1602-4.
Score: 0.001
-
CSF dopamine beta-hydroxylase in schizophrenia. Arch Gen Psychiatry. 1983 Jul; 40(7):743-7.
Score: 0.001
-
Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF. Relationship to antidepressant response. Arch Gen Psychiatry. 1983 Jun; 40(6):673-6.
Score: 0.001
-
CSF somatostatin in affective illness. Arch Gen Psychiatry. 1983 Apr; 40(4):409-12.
Score: 0.001
-
The effect of lithium on the osmoregulation of arginine vasopressin secretion. J Clin Endocrinol Metab. 1983 Feb; 56(2):295-9.
Score: 0.001
-
Neurohypophyseal function in affective illness. Psychopharmacol Bull. 1983; 19(3):426-31.
Score: 0.001
-
Effect of carbamazepine on cyclic nucleotides in CSF of patients with affective illness. Biol Psychiatry. 1982 Sep; 17(9):1037-45.
Score: 0.001
-
Cerebrospinal fluid hydroxylase cofactor in schizophrenia. Psychiatry Res. 1982 Apr; 6(2):145-51.
Score: 0.001
-
Central nervous system gamma-aminobutyric acid activity in man. Relationship to age and sex as reflected in CSF. Arch Neurol. 1982 Apr; 39(4):247-9.
Score: 0.001
-
Endorphins in the cerebrospinal fluid of psychiatric patients. Ann N Y Acad Sci. 1982; 398:399-412.
Score: 0.001
-
Depressed patients have decreased binding of tritiated imipramine to platelet serotonin "transporter". Arch Gen Psychiatry. 1981 Dec; 38(12):1315-7.
Score: 0.001
-
Endogenous opioid activity and beta-endorphin immunoreactivity in CSF of psychiatric patients and normal volunteers. Am J Psychiatry. 1981 Nov; 138(11):1457-62.
Score: 0.001
-
Relationship between urinary free cortisol and CSF opioid binding activity in depressed patients and normal volunteers. Psychiatry Res. 1981 Aug; 5(1):87-93.
Score: 0.001
-
The effect of pimozide on CSF norepinephrine in schizophrenia. Am J Psychiatry. 1981 Aug; 138(8):1045-50.
Score: 0.001
-
Slow and rapid onset of manic episodes: implications for underlying biology. Psychiatry Res. 1981 Apr; 4(2):229-37.
Score: 0.001
-
Effects of vasopressin on human memory functions. Science. 1981 Feb 06; 211(4482):601-3.
Score: 0.001
-
Lack of effect of carbamazepine on gamma-aminobutyric acid in cerebrospinal fluid. Neurology. 1980 Sep; 30(9):1008-11.
Score: 0.001
-
Immunoreactive calcitonin in cerebrospinal fluid of man. Brain Res. 1980 Aug 04; 194(2):598-602.
Score: 0.001
-
Rapid mood cycling and concomitant cortisol changes produced by cyproheptadine. Am J Psychiatry. 1980 Mar; 137(3):378-9.
Score: 0.001
-
Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry. 1980 Jan; 37(1):51-9.
Score: 0.001
-
Low cerebrospinal fluid gamma-aminobutyric acid content in seizure patients. Neurology. 1979 Sep; 29(9 Pt 1):1203-8.
Score: 0.001
-
Dopamine-beta-hydroxylase in the cerebrospinal fluid of psychiatric patients. Biol Psychiatry. 1978 Dec; 13(6):685-94.
Score: 0.001